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Abstract:  Neuronal  cells  are  extremely  vulnerable  and  have  a  limited  capacity  for  
self-repair in response to injury. For those reasons, there is obvious interest in limiting 
neuronal  damage. Mechanisms and strategies used in order to protect against neuronal 
injury,  apoptosis,  dysfunction,  and  degeneration  in  the  central  nervous  system  are 
recognized as neuroprotection. Neuroprotection could be achieved through several classes 
of natural and synthetic neuroprotective agents. However, considering the side effects of 
synthetic neuroprotective agents, the search for natural neuroprotective agents has received 
great attention. Recently, an increasing number of studies have identified neuroprotective 
properties of chitosan and its derivatives; however, there are some significant challenges 
that must be overcome for the success of this approach. Hence, the objective of this review 
is to discuss neuroprotective properties of chitosan and its derivatives. 
Keywords:  neuronal  cells;  neuroprotection;  neuroprotective  agents;  neuroprotective 
properties; chitosan and derivatives 
 
1. Introduction  
The brain is an amazing and critical organ for our life [1]. It is surrounded by layers of tissue called 
meninges and encased by the skull. There are two broad classes of cells in the brain, which are neuron 
and glia [2–4]. Even though neuronal cells are among the longest-living cell types in mammals, unlike 
many other cells, they have a limited capacity for self-repair in response to injury [5,6]. This condition 
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is compounded by the fact that neuronal cells are extremely vulnerable [7]. For this reason, there is an 
obvious interest in limiting the cell damage caused by various insults that trigger endogenous repair 
mechanisms. The mechanisms and strategies used in order to protect them against neuronal injury, 
apoptosis,  dysfunction  and  or  degeneration  in  the  central  nervous  system  (CNS)  are  called  as 
neuroprotection [8]. The goal of neuroprotection is to limit neuronal dysfunction or death after CNS 
injury in an attempt to maintain the highest possible integrity of cellular interactions in the brain, thus 
minimizing disturbance to neural function [9]. According to its mechanism, neuroprotection can be 
categorized  into  several  mechanisms  such  as:  antioxidant  (free  radical  trapper/scavenger)  [10,11];  
anti-inflammatory [12,13]; anti-exitotoxic [14]; apoptosis inhibitor [15]; gene expression modulator 
[16]; ion channel modulator [17,18]; metal ion chelator [19,20]; neurotrophic factor [21–23]; MMP 
inhibitor [24]; combined mechanism (combining two mechanisms or more) [25]. 
Many  categories  of  natural  and  synthetic  compounds  have  been  reported  to  possess  a 
neuroprotective activity. However, these synthetic neuroprotective agents are believed to have certain 
side effects such as dry mouth, tiredness, drowsiness, sleepiness, anxiety or nervousness, difficulty to 
balance,  etc.  [26].  Hence,  nowadays  researchers  have  a  great  interest  to  study  natural  bioactive 
compounds that can act as neuroprotective agents.  
The marine environment  is  been  known as  a  rich source of  bioactive chemical structures with 
promising biological activities such as neuroprotection [27]. Based on several studies, it is reported 
that  chitosan,  one  of  the  biologically  active  compounds  derived  from  the  sea,  has  potent 
neuroprotective properties. 
Over the last three decades, there have been a growing number of publications on chitosan and its 
derivatives  in  the  pharmaceutical  industry.  Chitosan  is  a  linear  polysaccharide  that  consists  of  
β-(1→4)-2-acetamido-d-glucose  and  β-(1→4)-2-amino-d-glucose  units  derived  from  partial 
deacetylation of chitin [28,29]. However, this polysaccharide has poor solubility, making it difficult to 
be  used  in  food  and  biomedical  applications  [30].  Considering  this  property  limitation,  some 
researchers  are  interested  in  converting  chitosan  into  oligosaccharides  [31].  Chitooligosaccharides 
(COS),  oligosaccharides  form  of  chitosan,  are  readily  soluble  in  water  due  to  their  shorter  chain 
lengths and free amino groups in D-glucosamine units [32]. Similar to chitosan, COS have positive 
charges resulting from removal of acetyl units from D-glucosamine residues. These properties enable 
COS to interact with negatively charged polymers, macromolecules and polyanions in an aqueous 
environment [33,34]. Both chitosan and COS are known to possess many biological activities such as 
antibacterial  [31,35],  immunoenhancing  [36],  antioxidant  [37],  matrix  metalloproteinase  (MMP) 
inhibition  [38–40],  anti-diabetic  [41],  anti-HIV  [42],  anti-inflammatory  activities  [43],  and  drug 
delivery [44], etc. Not only restricted to those activities, chemical modification will enhance and open 
various ways to utilize chitosan and COS [29]. The rationale for this is that a chemical modification 
will keep the original physiochemical and biochemical properties of chitosan and COS and bring the 
new properties of the group introduced to them at the same time [45].  
Recent  reviews  have  been  published  regarding  the  pharmaceutical  effects  of  chitosan  and  its 
derivatives. This review, however, focuses specifically on neuroprotective properties of chitosan and 
its derivatives. Mar. Drugs 2010, 8                       
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2. Suppressing Effect on β-Amyloid Formation 
The  most  common  neurodegenerative  disorder,  Alzheimer’s  disease  (AD),  is  an  irreversible, 
progressive brain disease affecting cognition [46]. The pathological hallmark of AD is the deposition 
of senile plaques (SPs) and neurofibrillary tangles (NFTs) [47]. SPs are composed of the β-amyloid 
(Aβ) peptides, which are cleaved from amyloid precursor proteins (APPs) by proteolysis enzymes such 
as β- and γ-secretase [48–50]. In APP proteolysis, it seems that the key enzyme is β-secretase, which is 
also known as β-amyloid cleavage enzyme (BACE-1), since it initiates the formation of Aβ [51]. 
Hence, BACE-1 represents a candidate biomarker, as well as a drug target for AD [52]. 
There  have  been  some  studies  on  BACE-1  inhibition  activities  and  Aβ  formation  inhibition 
activities of chitosan and its derivatives for a decade.  
Scheme 1. Synthesis of chitosan derivatives. 
O
O HO
OR
NHR1
O
O HO
OH
NHR1
R-Cl, NaOH
n n  
AE-chitosan  :  R = (CH2)2NH2 : R1 = H, COCH3 
DMAE-chitosan  :  R = (CH2)2N(CH3)2 : R1 = H, COCH3 
DEAE-chitosan  :  R = (CH2)2N(CH2CH3)2 : R1 = H, COCH3 
BACE-1  inhibition  activity  of  chitosan  derivatives have been reported by Je  et  al.  [28].  They 
prepared chitosan with two degrees of deacetylation (90% and 50%) and grafted amino functionality 
into chitosan to improve the solubility and bioactivity. The synthesized reaction of chitosan derivatives 
are presented in Scheme 1. Chitosan derivatives were designated as aminoethyl (AE-chitosan) (90%), 
dimethylaminoethyl  (DMAE-chitosan)  (90%),  and  diethylaminoethyl  (DEAE-chitosan)  (90%) 
prepared  from  90%  deacetylated  chitosan,  and  AE-chitosan  (50%),  DMAE-chitosan  (50%),  and 
DEAE-chitosan  (50%)  prepared  from  50%  deacetylated  chitosan.  The  potencies  of  chitosan 
derivatives are expressed as an IC50 value, which is the BACE-1 inhibitor concentration leading to 
50% inhibition of BACE-1 activity. AE-chitosan (90%) shows strongest inhibitory activity compared 
to  other  derivatives.  Moreover,  the  inhibition  modes  of  BACE-1  catalyzed  by  chitosan  and  its 
derivatives have been determined by Dixon plots. Based on the Dixon plots, the inhibition constant 
(Ki) of AE-chitosan (90%) is 85 μg/mL. They suggested that the free amino groups at the C-2 and C-6 
positions play an important role in BACE-1 inhibitory activity; however, the free amino group at C-2 
is a minor factor according to the above results. 
An investigation of BACE-1 inhibitory activity of COS was done by Byun et al. [53]. Nine kinds of 
hetero-COS with different degrees of deacetylation and molecular weight were prepared by using an 
ultrafiltration  (UF)  membrane  reactor  [35].  The  deacetylated  chitosan  of  90,  75,  and  50%  were 
hydrolyzed and fractionated by passing them through three UF membranes of molecular weight cut-off 
(MWCO)  10,  5,  and  1  kDa.  The  hetero-COSs  were  named  90-HMWCOSs,  75-HMWCOSs,  
50-HMWCOSs,  90-MMWCOSs,  75-MMWCOSs,  50-MMWCOSs,  90-LMWCOSs,  75-LMWCOSs, 
50-LMWCOSs respectively. 90-MMWCOSs which are 90% deacetylated COS with molecular weight Mar. Drugs 2010, 8                       
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3–5 kDa, exhibited the highest BACE-1 inhibitory activity (25–42 mM) compared to the others. The 
inhibitor  was  found  to  have  a  noncompetitive  by  Dixon  plot,  and  the  Ki  of  90-MMWCOSs  was  
3.87–6.47  mM.  The  study  of  Byun  and  his  colleagues  indicated  that  degree  of  deacetylation  and 
sulfations at the C-2 position of COS has an effect on BACE-1 inhibitory activity. A further amine 
group at C-2 position was shown to be beneficial for BACE-1 inhibitory activity. 
Based on the hypothesis that the increase of an important product of oxidation may induce Aβ 
formation, Khodagholi et al. [54] studied the effect of chitosan in NT2 neuron cells induced by H2O2 
and FeSO4. NT2 neuronal cells are a widely accepted experimental model to study the regulation of 
APP metabolism and the pathogenesis of AD [55]. In their study, they found that Aβ formation by 
NT2 neurons pretreated with chitosan was significantly lower than that of control cells exposed only to 
H2O2. The Aβ levels rose from 30.96 pg/mL in H2O2-treated cells to 22.2 and 18.35 pg/mL in the 
presence  of  0.1  and  0.5%  w/v  chitosan,  respectively.  This  study  indicates  that  Aβ  level  can  be 
controlled by treatment with this chitosan, suggesting a protective effect of chitosan in AD.  
Almost all currently available medications for AD are cholinesterase inhibitors. Considering these 
reasons,  the  suppression  of  β-amyloid  formation  by  chitosan  and  its  derivatives  will  enhance  the 
medications for AD. However, further studies are needed with clinical trials for the application of 
chitosan and its derivatives in AD medications. 
3. Acetylcholinesterase Inhibitory Activity  
The pathogenesis of AD has been linked to a deficiency in the brain neurotransmitter
 acetylcholine 
(ACh) [56]. This was stated in the cholinergic hypothesis which was raised three decades ago, that a 
serious loss of cholinergic function in the CNS contributes significantly to the cognitive symptoms 
associated with AD [57]. The inhibition of acetylcholinesterase (AChE) enzyme, which catalyzes the 
breakdown of ACh, may be one of the most realistic approaches to the symptomatic treatment of  
AD [56,58,59]. 
Recently,  several  studies  on  chitosan  and  its  derivatives  have  identified  their  potential  as 
acetylcholinesterase inhibitors (AChEIs). The AChEIs activity of COS and its derivatives is discussed 
below as well as summarized in Table 1. 
Table 1. Cholinesterase inhibitory activities of COS derivatives. 
COS  IC50  Ref 
90-HMWCOS  2.59 mg/mL   [60] 
90-MMWCOS  1.67 mg/mL   [60] 
90-LMWCOS  3.52 mg/mL   [60] 
50-HMWCOS  1.98 mg/mL   [60] 
50-MMWCOS  2.93 mg/mL   [60] 
50-LMWCOS  >4.00 mg/mL   [60] 
AE-COS  56.5 ±  0.26 μg/mL   [61] 
DMAE-COS  24.1 ± 0.39 μg/mL   [61] 
DEAE-COS  9.2 ± 0.33 μg/mL   [61] 
Eserine 
a  0.0089 ± 0.00005 μg/mL   [61] 
a positive control. Mar. Drugs 2010, 8                       
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Lee et al. [60] studied AChEIs activity of six kinds of COS with different molecular weight and 
degrees  of deacetylation.  In  their study,  90-COS and  50-COS were  prepared  from 90%  and 50% 
deacetylated chitosan and further fractionated into three kinds of COS, high molecular weight (HMW) 
(5,000–10,000 dalton), medium molecular weight (MMW) (1,000–5,000 dalton), and low molecular 
weight (LMW) (below 1,000 dalton) using an ultrafiltration membrane system as described by Kim et 
al. [35]. 90-COS has stronger AChEIs activity than 50-COS. Among 90-COS, 90-MMWCOS (90% 
deacetylated COS with molecular weight 1000–5000 Da) showed the strongest AChEIs with IC50 
value of 1.67 mg/mL (Table 1). Moreover, Lee et al. also investigated the level of AChE protein 
expression and AChEIs activity in PC12 cell lines using Ellman’s evaluation. The results showed that  
90-MMWCOS suppressed the AChE protein expression and increased the AChEIs in a dose dependant 
manner.  These  findings  suggest  that  degree  of  deacetylation  of  COS  is  the  key  factor  for  the  
AChEIs activity. 
Furthermore, Yoon et al. [61] synthesized COS derivatives with different substitution groups. In 
their study, the synthesis of COS derivatives was accomplished by the displacement of the hydroxyl 
group  at  the  C-6  of  the  pyranose  ring  and  replaced  with  aminoethyl  (AE),  dimethylaminoethyl 
(DMAE)  and  diethylaminoethyl  (DEAE)  groups.  The  chemical  structures  were  determined  as  
AE-COS,  DMAE-COS  and  DEAE-COS,  in  sequence.  Eserine,  a  parasympathomimetic  and  a 
reversible cholinesterase inhibitor, was used as the positive control in their study. Among three COS 
derivatives, DEAE-COS has the strongest AChEIs activity with IC50 values of 9.2 ±  0.33 μg/mL. 
DMAE- and DEAE-COS were identified as competitive AChEIs according to the Lineweaver–Burk 
plot. These findings suggest that the chemical modification will enhance the utilization of COS as 
AChEIs,  and  their  inhibitory  activity  depends  on  the  hydrophobic  nature  of  the  group  that  is 
introduced to them. 
AChEIs,  which  provide  modest  symptomatic  improvement  and  are  able  to  delay  the  loss  of 
functional abilities, is a promising medication for AD patients. The AChEIs activity of COS and its 
derivatives indicate that COS derivatives might be a beneficial material in the prevention or treatment 
of AD. Furthermore, mechanistic studies, particularly those that investigate how these compounds 
inhibit AChE activity in cellular systems, will be required in the future. 
4. Anti-Neuroinflammatory  
In principle, inflammation is the first response of a human body’s immune system to pathogens or 
irritation  [62,63].  A  growing  number  of  studies  are  discovering  intriguing  links  between  chronic 
inflammation and a number of neurodegenerative disorders [62]. The neuroinflammation process plays 
a  pivotal  role  in  the initiation  and  progression  of various  neurodegenerative  diseases.  Recently,  a 
number of studies have found anti-neuroinflammatory activity of chitosan and its derivatives. 
Kim et al. [64] reported that high molecular weight water soluble chitosan (WSC) inhibits the 
production of pro-inflammatory cytokine in human astrocytoma cells activated by Aβ peptide 25–35 
(Aβ25–35)  and  interleukin-1β  (IL-1β).  In  their  study,  they  used  the  human  astrocytoma  cell  line  
(CCF-STTG1) as an in vitro AD model. The effects of WSC on pro-inflammatory cytokines such as 
tumor  necrosis  factor-α  (TNF-α)  and  interleukin-6  (IL-6)  were  evaluated  by  enzyme-linked 
immunosorbent assay (ELISA) and western blotting. The secretion and expression of TNF-α and IL-6 Mar. Drugs 2010, 8                       
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were significantly inhibited by pretreatment with 1 and 10 µ g/mL of WSC. Moreover, the expression 
of inducible nitric-oxide synthase (iNOS) induced by Aβ25–35 and IL-1β was partially inhibited by 
treatment  with  WSC.  However,  those  findings  need  further  investigation  to  find  whether  WSC 
regulates  the  transcription  factor  and  signaling  molecules  with  concerns  to  the  production  of 
inflammatory cytokines and neurotoxic components. 
Another study conducted by Khodagholi et al. focused on the anti-neuroinflammatory effect of 
chitosan and its derivatives on NT2 neuronal cells. Chitosan exerts anti-neuroinflammatory action by  
upregulation  of  heat  shock  protein  70  (Hsp-70)  and  inhibits  the  activation  of  NF-κB  [54].  The  
anti-inflammatory  mechanism  of  Hsp-70  is  mediated  by  the  binding  of  Hsp-70  to  NF-κB  and  its 
subsequent inhibition [65]. A pre-treatment with 0.1 and 0.5% (w/v) chitosan prior to H2O2 and FeSO4 
exposure has been proved to increase the level of heat shock protein (Hsp-70) to 1.4- and 1.6-times, 
respectively.  
Several  studies  have  shown  anti-neuroinflammatory  activity  of  chitosan  and  its  derivatives; 
however, further studies about anti-neuroinflammatory activity of chitosan and its derivatives in other 
neuronal cells such as microglia are needed. Moreover, various intracellular signaling pathways also 
need  to  be  investigated  in  order  to  obtain  a  better  understanding  of  the  underlying  
anti-neuroinflammatory mechanism of chitosan and its derivatives.  
5. Apoptosis Inhibitors 
The  elimination  of  cells  by  apoptosis  or  programmed  cell  death  is  a  fundamental  event  in 
development,  whereby  multi-cellular  organisms  regulate  cell  numbers  or  eliminate  cells  that  are 
functionally redundant or potentially detrimental to the organism [66]. Many human diseases such as 
acquired  immunodeficiency  syndrome,  neurodegenerative  disorders,  and  cancer  can  be  attributed 
directly or indirectly to a derangement of apoptosis resulting in either cell accumulation, in which cell 
eradication or cell turnover is impaired or cell loss, in which the apoptotic programs are inadvertently 
triggered [67]. In neurodegenerative disorders, apoptosis might be pathogenic, and targeting it might 
mitigate neurodegenerative disorders [68]. Some studies on chitosan have found biological activity of 
chitosan, COS and its derivatives in targeting apoptosis in brain cells.  
A study carried out by Koo et al. successfully showed that high molecular weight water soluble 
chitosan  (WSC)  was  able  to  protect  against  apoptosis  in  human  astrocytoma  cells  (CCF-STTG1) 
induced by serum starvation [69]. In their study, they used WSC, which has a molecular weight of  
300 kDa and degree of deacetylation over 90%, which was produced by using a multi-step membrane 
separation process. Based on the cytotoxicity test, WSC (10 μg/mL) was able to inhibit cell death 
significantly  compared  to  the  control  group.  Furthermore,  in  order  to  induce  apoptosis  by  serum 
starvation, they incubated CCF-STTG1 cells for 48 h in medium supplemented with only 0.1% FBS. 
The  serum  starvation-induced  apoptosis  of  CCF-STTG1  cells  was  determined  by  flow  cytometry. 
Their results suggested that when the cells treated with WSC (10 μg/mL) were exposed to serum 
starved-medium, apoptosis of CCF-STTG1 cells was almost completely inhibited compared to the 
effect of serum starved-medium alone. Supporting the flow cytometry, they also showed that DNA 
fragmentation  in  a  ladder  pattern,  which  is  characteristic  of  apoptosis,  was  not  detected  in  
CCF-STTG1  cells  pre-treated  with  WSC  (10  μg/mL).  It  is  known  that  serum  starvation  induces Mar. Drugs 2010, 8                       
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apoptosis through the activation of p53, based on their Western blot data; WSC can prevent serum 
starvation-induced  apoptosis  via  blocking  p53  activation.  Although  their  study  did  not  directly 
demonstrate general cell death of CCF-STTG1 astrocytoma cells because only morphological changes 
have been observed, their finding might suggest that WSC can promote neuroprotective properties in 
the brain. 
Recently, the protective effect of COS, with a molecular weight 800 Da, against glutamate-induced 
neurotoxicity  in  cultured  hippocampal  neurons  has  been  reported  [70].  In  their  study  they  used 
glutamate  as  a  model,  because  glutamate  accumulation  in  the  CNS  and  excessive  stimulation  of 
glutamate receptors induces potent neurotoxic action, which is specifically referred to as excitotoxicity, 
and is involved in neuronal damage and degenerative disorders in the CNS. A glutamate concentration 
of 125 μM was chosen in their study. Hoechst staining and flow cytometry with annexin V/PI staining 
showed that in this concentration rat hippocampal neurons underwent extensive apoptotic-like cell 
death characterized by neuronal morphology. Based on the cell viability assessments, together with 
Hoechst 33342 staining and flow cytometry for cell apoptosis analysis, pre-treatment with COS was 
able to attenuate apoptosis in hippocampal neurons cells in a dose dependent manner. Moreover, they 
also measured the change in caspase-3 activity during cell treatment. A three- to four-fold increase in 
caspase-3 activity was found in cultured hippocampal neurons at 18 h after a 15-min exposure to 
glutamate, and pretreatment with 1.0 and 2.0 mg/mL of COS prevented cells from glutamate-induced 
increases  in  caspase-3  activity.  The  increase  of  [Ca
2+]  has  been  postulated  to  be  associated  with 
glutamate-induced cell death. In cultured hippocampal neurons exposed to 125 μM glutamate, [Ca
2+] 
was promptly elevated, and then leveled off with significantly higher values compared to that for 
control group throughout a recording period of 15 min. In contrast, [Ca
2+] in cultured hippocampal 
neurons pretreated with COS (1.0 mg/mL) showed significantly lower values than those for cultured 
hippocampal neurons without COS pretreatment over a recording period of 15 min, suggesting that 
COS pretreatment significantly inhibited the [Ca
2+] increase. Since glutamate-evoked cell injury in 
hippocampal neurons is involved in many CNS disorders, their study may raise the possibility of 
developing COS as a potential agent for the prevention and treatment of some CNS diseases. 
Apoptosis  inhibition  activity  of  chitosan  and  COS  might  be  extended  to  the  intervention  of 
neurodegenerative disorders. However, further studies, such as in vivo tests, are needed to clarify the 
neuroprotective properties of chitosan and COS.  
6. Other Activities 
The possible role of chitosan in preventing oxidative stress-induced by amyloid β formation in NT2 
neuron cells was investigated by Khodagholi et al. [54]. On the other hand, the evaluation utility of 
chitosan nanoparticles with an in-vitro model of acrolein-mediated cell injury using PC-12 cells was 
investigated  by  Cho  et  al.  [71].The  particles  effectively,  and  statistically,  reduced  damage  to 
membrane integrity, secondary oxidative stress, and lipid peroxidation. Their study suggests that a 
chitosan nanoparticle-based therapy to interfere with "secondary" injury is possible.  
Moreover, the development of an effective delivery system is needed to provide sufficient drug 
concentration into the brain to prevent cell death. Using avidin (SA)-biotin (BIO) technology, Aktas et 
al. [72] describe the design of chitosan (CS) nanospheres conjugated with poly(ethylene glycol) (PEG) Mar. Drugs 2010, 8                       
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bearing the OX26 monoclonal antibody whose affinity for the transferrin receptor (TfR) may trigger 
receptor mediated transport across blood-brain barrier. Their findings indicate that this novel targeted 
nanoparticulate drug delivery system was able to translocate into the brain tissue after intravenously 
administration.  Consequently,  chitosan  is  a  promising  carrier  for  the  transport  of  the  anticaspase 
peptide Z-DEVD-FMK into the brain.  
7. Conclusions 
In recent years, the marine environment has shown to provide extremely rich biological active 
compounds.  Chitosan,  one  of  the  bioactive  compounds  derived  from  the  sea,  has  been  shown  to 
possess many biological activities. In fact, the interest in chitosan and its derivatives for the treatment 
of neurological disorders appear to be an emerging field. Some of the representative’s examples are 
presented in this review with a focus on neuroprotective properties of chitosan and its derivatives. 
According to presented data, it seems that chitosan and its derivatives are promising neuroprotective 
agents,  as  they  showed  neuroprotective  properties  such  as:  suppression  of  β-amyloid  formation, 
AChEIs, anti-neuroinflammatory activity, apoptosis inhibitors, etc. Up until now, most neuroprotective 
activities of chitosan and its derivatives have been observed in vitro. Therefore, further studies are 
needed  in  order  to  investigate  their  activity  in  mouse  model  systems  and/or  human  subjects.  In 
conclusion, these results reveal the potential of chitosan and its derivatives as potential therapeutic 
candidates for neurodegenerative disorder and their involvement in the future pharmaceuticals are 
promising. 
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